Overview

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

Status:
Recruiting

Trial end date:
2024-09-01

Target enrollment:

Participant gender:

Summary

The primary specific aim is to evaluate the use of intranasal scopolamine gel and sensory augmentation as an integrated countermeasure to mitigate motion sickness and enhance sensorimotor performance. The proposed intranasal scopolamine gel formulation (Defender Pharmaceuticals, Inc.) offers a safe non-invasive method to self-administer with a rapid onset of action. This study involves a comparison of motion sickness outcome measures when administering intranasal scopolamine gel versus placebo (Aim 1a), and then when administering intranasal scopolamine gel versus placebo with a sensory augmentation belt (Aim 1b).

Phase:

Phase 2

Details

Lead Sponsor:

Repurposed Therapeutics, Inc.

Collaborator:

National Aeronautics and Space Administration (NASA)

Treatments:

Butylscopolammonium Bromide
Scopolamine